What is the current Global Hormone Replacement Therapy Market size?

The Global Hormone Replacement Therapy Market is projected to register a CAGR of 7.59% during the forecast period (2024-2029) Read More

Who are the key players in Global Hormone Replacement Therapy Market?

Abbott Laboratories, Novartis AG, Pfizer Inc., Merck KGaA and Bayer AG are the major companies operating in the Global Hormone Replacement Therapy Market. Read More

Which is the fastest growing region in Global Hormone Replacement Therapy Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Hormone Replacement Therapy Market?

In 2024, the North America accounts for the largest market share in Global Hormone Replacement Therapy Market. Read More

What years does this Global Hormone Replacement Therapy Market cover?

The report covers the Global Hormone Replacement Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Hormone Replacement Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Hormone Replacement Therapy (HRT) Market

Hormone Replacement Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Global HRT Market Report is Segmented by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, and Testosterone Replacement), Route of Administration (Oral, Parenteral, and Other Routes of Administration), Indication (Menopause, Hypothyroidism, Growth Hormone Deficiency, and Other Indications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for all the above segments.

Hormone Replacement Therapy (HRT) Industry Overview

The market is moderately competitive, with few major players dominating the market globally. The key companies are Abbott Laboratories, Bayer AG, Merck KGaA, Novartis AG, and Pfizer Inc. However, there are efforts being made by new players to enter the hormone replacement therapy market. Additionally, the key players are focused on global product portfolio expansion through acquisitions and collaborations with companies that complement their portfolios. For instance, in December 2020, the US FDA approved Thyquidity (levothyroxine) oral solution, of VistaPharm, for replacement therapy of primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, along with an additional approval as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.